Identification

Name
Vemurafenib
Accession Number
DB08881  (DB05238)
Type
Small Molecule
Groups
Approved
Description

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[2] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[3] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [8]

Structure
Thumb
Synonyms
  • BRAF(V600E) Kinase Inhibitor RO5185426
External IDs
PLX-4032 / PLX4032 / RG-7204 / RG7204 / RO-51-85426 / RO-5185426 / RO5185426
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZelborafTablet240 mgOralHoffmann La Roche2012-03-05Not applicableCanada
ZelborafTablet, film coated240 mg/1OralGenentech, Inc.2011-08-17Not applicableUs
ZelborafTablet, film coated240 mgOralRoche Registration Gmb H2012-02-17Not applicableEu
Categories
UNII
207SMY3FQT
CAS number
918504-65-1
Weight
Average: 489.922
Monoisotopic: 489.072546264
Chemical Formula
C23H18ClF2N3O3S
InChI Key
GPXBXXGIAQBQNI-UHFFFAOYSA-N
InChI
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
IUPAC Name
N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
SMILES
CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1

Pharmacology

Indication

Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[3] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[4] Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[9] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[5]

Associated Conditions
Pharmacodynamics

BRAF activation results in cell growth, proliferation, and metastasis. BRAF is an intermediary molecule in MAPK whose activation depends on ERK activation, elevation of cyclin D1 and cellular proliferation. The mutation V600E produces a constitutively form of BRAF. Vemurafenib has been shown to reduce all activation markers related to BRAF; in clinical trials, vemurafenib treatment showed a reduction of cytoplasmic phosphorylated ERK and a cell proliferation driven by Ki-67. Studies also reported decrease in MAPK-related metabolic activity.[3] All the different reports indicate thet Vemurafenib generates an almost complete inhibition of the MAPK pathway.

Mechanism of action

Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. Vemurafenif is a small molecule that interacts as a competitive inhibitor of the mutated species of BRAF. It is especially potent against the BRAF V600E mutation. Vemurafenib blocks downstream processes to inhibit tumour growth and eventually trigger apoptosis. Vemurafenib does not have antitumour effects against melanoma cell lines with the wild-type BRAF mutation.[10]

TargetActionsOrganism
ASerine/threonine-protein kinase B-raf
inhibitor
Human
Absorption

Vemurafenib is well absorbed after oral administration.[6] Peak concentrations are reached in 3 hours when an oral dose of 960 mg twice daily for 15 days has been given to patients. In the same conditions, Vemurafenib presents a Cmax of 62 mcg/ml and AUC of 601 mcg h/ml.[Label] It is unknown how food affects the absorption of vemurafenib. It presents an accumulation ratio of 7.36 after repeating doses of 960 mg [10]

Volume of distribution

The estimation of the volume of distribution for Vemurafenib is 106 L.[7]

Protein binding

Vemurafenib highly binds to plasma proteins where >99% of the administered dose will be found protein bound to serum albumin and alpha-1 acid glycoprotein.[7]

Metabolism

Vemurafenib is metabolized by CYP3A4 and the metabolites make up 5% of the components in plasma. The parent compound makes up for the remaining 95%.[7]

Route of elimination

Analysis showed that 94% of administered Vemurafenib is excreted via feces and 1% is excreted by urine.[7]

Half life

The elimination half-life of Vemurafenib is estimated to be 57 hours (range of 30-120 hours).[7]

Clearance

The total body clearance is 31 L/day.[7]

Toxicity

In the few toxicity reports, it has been shown an increased in the development of cutaneous squamous cell carcinomas or acceleration in pre-existant tumor growth.[Label]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
5'-Deoxy-5'-MethylthioadenosineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AbafunginThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Abafungin.Investigational
AbediterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Abediterol.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Vemurafenib.Approved, Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Abexinostat.Investigational
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Vemurafenib.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Vemurafenib.Approved, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Vemurafenib.Approved, Investigational
AcepromazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Vemurafenib.Approved
AcetophenazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Vemurafenib can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vemurafenib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Vemurafenib.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Vemurafenib.Approved, Vet Approved
AdinazolamThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Adinazolam.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Vemurafenib.Approved
AgomelatineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Alaproclate.Experimental
AlbaconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Albaconazole.Investigational
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Vemurafenib.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Vemurafenib.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Vemurafenib.Experimental, Investigational
AlfentanilThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Alfentanil.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Vemurafenib.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Vemurafenib.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Vemurafenib.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Vemurafenib.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Vemurafenib.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Vemurafenib.Approved
AlosetronThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Alosetron.Approved, Withdrawn
alpha-Tocopherol acetateThe serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Vemurafenib.Approved
AlphacetylmethadolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Alphaprodine.Illicit
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Vemurafenib.Approved, Illicit, Investigational
AlvocidibThe serum concentration of Vemurafenib can be decreased when it is combined with Alvocidib.Experimental, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Vemurafenib.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Vemurafenib.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Vemurafenib.Approved, Investigational
AmineptineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amineptine.Illicit, Withdrawn
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Vemurafenib.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Vemurafenib.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Vemurafenib.Approved
AmodiaquineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amoxapine.Approved
AmperozideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Vemurafenib.Approved, Investigational
AnagrelideThe serum concentration of Anagrelide can be increased when it is combined with Vemurafenib.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Vemurafenib.Approved, Investigational, Withdrawn
AniracetamThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aniracetam.Experimental
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Vemurafenib.Approved, Investigational
ApalutamideThe serum concentration of Vemurafenib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Vemurafenib.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Vemurafenib.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Vemurafenib.Approved, Investigational
ArbutamineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Arbutamine.Approved
ArformoterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Vemurafenib.Approved, Investigational
AripiprazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Vemurafenib.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemether.Approved
ArtemisininThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemisinin.Investigational
ArtemotilThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemotil.Approved
ArtenimolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artenimol.Approved, Investigational
ArtesunateThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artesunate.Approved, Investigational
AsenapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Vemurafenib.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Vemurafenib.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Vemurafenib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Vemurafenib.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Vemurafenib.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Vemurafenib.Approved
AtovaquoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Atovaquone.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Vemurafenib.Approved
AvatrombopagThe serum concentration of Avatrombopag can be decreased when it is combined with Vemurafenib.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Vemurafenib.Approved, Investigational
AzaperoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Azaperone.Investigational, Vet Approved
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Vemurafenib.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Azithromycin.Approved
BambuterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bambuterol.Approved, Investigational
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Vemurafenib.Investigational
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Vemurafenib.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Vemurafenib.Approved
BelinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Belinostat.Approved, Investigational
BenactyzineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Benactyzine.Withdrawn
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Vemurafenib.Approved, Investigational
BenidipineThe serum concentration of Benidipine can be increased when it is combined with Vemurafenib.Approved, Investigational
BenperidolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Benperidol.Approved, Investigational
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Vemurafenib.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Vemurafenib.Approved
BeraprostThe serum concentration of Beraprost can be increased when it is combined with Vemurafenib.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Vemurafenib.Approved, Vet Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Vemurafenib.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Vemurafenib.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Vemurafenib.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Vemurafenib.Approved, Investigational
BezitramideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bezitramide.Experimental, Illicit, Withdrawn
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Vemurafenib.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Vemurafenib.Approved, Investigational
BifemelaneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bifeprunox.Investigational
BifonazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bifonazole.Approved, Investigational
BioallethrinThe serum concentration of Bioallethrin can be decreased when it is combined with Vemurafenib.Approved, Experimental
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Vemurafenib.Approved
BitolterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bitolterol.Withdrawn
BlonanserinThe serum concentration of Blonanserin can be decreased when it is combined with Vemurafenib.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Vemurafenib.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Vemurafenib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Vemurafenib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Vemurafenib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Vemurafenib.Approved, Investigational
BrexpiprazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Brexpiprazole.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be decreased when it is combined with Vemurafenib.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Vemurafenib.Approved
BrivaracetamThe serum concentration of Brivaracetam can be decreased when it is combined with Vemurafenib.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Vemurafenib.Approved, Illicit, Investigational
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Vemurafenib.Approved, Investigational
BromperidolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bromperidol.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Vemurafenib.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Vemurafenib.Approved
BufexamacThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bufexamac.Approved, Experimental
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Vemurafenib.Approved, Investigational
BuprenorphineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Vemurafenib.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Vemurafenib.Approved, Investigational
ButaperazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Butaperazine.Experimental
ButoconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Butoconazole.Approved
ButorphanolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Butorphanol.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Butriptyline.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Vemurafenib.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Vemurafenib.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Vemurafenib.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Vemurafenib.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Vemurafenib.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Vemurafenib.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Vemurafenib.Approved
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Vemurafenib.Approved, Investigational
CarbamazepineThe serum concentration of Vemurafenib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Vemurafenib.Approved
CarbomycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Carbomycin.Vet Approved
CarboplatinThe serum concentration of Vemurafenib can be decreased when it is combined with Carboplatin.Approved
CarfentanilThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Vemurafenib.Approved, Investigational
CariprazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cariprazine.Approved, Investigational
CarmustineThe serum concentration of Carmustine can be increased when it is combined with Vemurafenib.Approved, Investigational
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Vemurafenib.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Vemurafenib.Approved, Investigational
CeliprololThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Celiprolol.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Vemurafenib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Vemurafenib.Approved, Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Vemurafenib.Approved
CG-200745The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with CG-200745.Investigational
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Vemurafenib.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Vemurafenib.Approved, Illicit, Investigational
ChloroquineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Vemurafenib.Approved
ChlorproethazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Chlorproethazine.Experimental
ChlorproguanilThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Chlorproguanil.Investigational
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Vemurafenib.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Vemurafenib.Approved, Nutraceutical
CholesterolThe serum concentration of Vemurafenib can be decreased when it is combined with Cholesterol.Approved, Investigational
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Vemurafenib.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Vemurafenib.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Vemurafenib.Approved, Investigational
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Vemurafenib.Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Vemurafenib.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Vemurafenib.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Vemurafenib.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Citalopram.Approved
CladribineThe serum concentration of Vemurafenib can be decreased when it is combined with Cladribine.Approved, Investigational
ClarithromycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clarithromycin.Approved
ClemastineThe metabolism of Vemurafenib can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Vemurafenib.Approved, Investigational
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Vemurafenib.Approved, Illicit
ClofarabineThe serum concentration of Vemurafenib can be decreased when it is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Vemurafenib.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Vemurafenib.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Vemurafenib.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Vemurafenib.Approved, Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Vemurafenib.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Vemurafenib.Approved
ClopenthixolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Vemurafenib.Approved
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Vemurafenib.Approved, Illicit
ClothiapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clothiapine.Experimental
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Vemurafenib.Approved, Illicit
ClotrimazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clozapine.Approved
CobicistatThe metabolism of Vemurafenib can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Vemurafenib.Approved, Investigational
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Vemurafenib.Approved, Illicit
CodeineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Vemurafenib.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Vemurafenib.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Vemurafenib.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Vemurafenib.Approved, Investigational
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Vemurafenib.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Vemurafenib.Approved
CUDC-907The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with CUDC-907.Investigational
CurcuminThe metabolism of Vemurafenib can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cyclobenzaprine.Approved
Cycloguanil embonateThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cycloguanil embonate.Experimental
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Vemurafenib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Vemurafenib.Experimental
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Vemurafenib.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Vemurafenib.Approved
DabrafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe serum concentration of Dacarbazine can be increased when it is combined with Vemurafenib.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Vemurafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Vemurafenib.Approved, Investigational
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Vemurafenib.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Vemurafenib.Approved
DapiprazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dapiprazole.Approved
DapsoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dapsone.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Vemurafenib.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Vemurafenib.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Vemurafenib.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Vemurafenib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Vemurafenib.Approved
DeanolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Deanol.Experimental
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Vemurafenib.Approved, Investigational
DeferasiroxThe serum concentration of Vemurafenib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be decreased when it is combined with Vemurafenib.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Vemurafenib.Approved
DelafloxacinThe serum concentration of Vemurafenib can be decreased when it is combined with Delafloxacin.Approved, Investigational
DelamanidThe serum concentration of Delamanid can be decreased when it is combined with Vemurafenib.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Vemurafenib.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Vemurafenib.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Desipramine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vemurafenib.Approved
DesvenlafaxineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Desvenlafaxine.Approved, Investigational
DeutetrabenazineThe serum concentration of Deutetrabenazine can be increased when it is combined with Vemurafenib.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Vemurafenib.Approved
DexfenfluramineThe serum concentration of Dexfenfluramine can be increased when it is combined with Vemurafenib.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe serum concentration of Dexlansoprazole can be decreased when it is combined with Vemurafenib.Approved, Investigational
DextofisopamThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dextofisopam.Investigational
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Vemurafenib.Approved
DextromoramideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dezocine.Approved, Investigational
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Vemurafenib.Approved, Illicit, Investigational, Vet Approved
DibenzepinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dibenzepin.Experimental
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Vemurafenib.Approved, Vet Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Vemurafenib.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Vemurafenib.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Vemurafenib.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Vemurafenib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vemurafenib.Approved
Dihydro-alpha-ergocryptineThe serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Vemurafenib.Approved
DihydrocodeineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Vemurafenib.Approved, Investigational
DihydroetorphineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Vemurafenib.Approved, Investigational
DimetacrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dimetacrine.Approved, Withdrawn
DinoprostoneThe serum concentration of Dinoprostone can be increased when it is combined with Vemurafenib.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Vemurafenib.Approved, Investigational
DiphenoxylateThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dipivefrin.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Vemurafenib.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Disopyramide.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Vemurafenib.Approved
DixyrazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Vemurafenib.Approved, Investigational
DofetilideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dolasetron.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Vemurafenib.Approved
DomperidoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Vemurafenib.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Vemurafenib.Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dosulepin.Approved
DoxepinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Vemurafenib.Approved, Investigational
DoxycyclineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with DPDPE.Experimental
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Vemurafenib.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dronedarone.Approved
DroperidolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Droperidol.Approved, Vet Approved
DroxidopaThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Vemurafenib.Approved, Investigational
EconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Econazole.Approved
EcopipamThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Vemurafenib.Approved
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Vemurafenib.Approved, Investigational
EfinaconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Efinaconazole.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Vemurafenib.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Vemurafenib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Vemurafenib.Approved
EltrombopagThe serum concentration of Eltrombopag can be increased when it is combined with Vemurafenib.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Vemurafenib.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Vemurafenib.Approved, Investigational
EnoxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Enoxacin.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Vemurafenib can be decreased when it is combined with Enzalutamide.Approved
EphedraThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Vemurafenib.Approved, Investigational
EpinephrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Epinephrine.Approved, Vet Approved
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Vemurafenib.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Vemurafenib.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Vemurafenib.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Vemurafenib.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Vemurafenib.Approved
EribulinEribulin may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Vemurafenib.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Vemurafenib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Esmirtazapine.Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Vemurafenib.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Vemurafenib.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Vemurafenib.Approved, Investigational
EstriolThe serum concentration of Estriol can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Vemurafenib.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Vemurafenib.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Vemurafenib.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Vemurafenib.Approved, Investigational
EtafedrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Etafedrine.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Vemurafenib.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Vemurafenib.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Vemurafenib.Approved
EthylmorphineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ethylmorphine.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be decreased when it is combined with Vemurafenib.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Vemurafenib.Approved, Investigational
EtoperidoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Vemurafenib.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Vemurafenib.Approved, Investigational
EtorphineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Vemurafenib.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Vemurafenib.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Vemurafenib.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Vemurafenib.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Vemurafenib.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Vemurafenib.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Vemurafenib.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Vemurafenib.Approved, Investigational
FencamfamineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Vemurafenib.Approved
FenoterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fenticonazole.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Vemurafenib.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Vemurafenib.Approved, Investigational
FidaxomicinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fidaxomicin.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Vemurafenib.Approved
FingolimodThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fingolimod.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fleroxacin.Approved
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Vemurafenib.Approved, Investigational
FluanisoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluanisone.Experimental
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Vemurafenib.Approved
FluconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluconazole.Approved, Investigational
FlumatinibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flumatinib.Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flumequine.Withdrawn
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Vemurafenib.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Vemurafenib.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Vemurafenib.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Vemurafenib.Approved, Investigational
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Vemurafenib.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Vemurafenib.Approved, Illicit, Investigational
FluspirileneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluspirilene.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Vemurafenib.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Vemurafenib.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be decreased when it is combined with Vemurafenib.Approved
FlutrimazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Flutrimazole.Experimental
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Vemurafenib.Approved
FluvoxamineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluvoxamine.Approved, Investigational
Folic AcidThe serum concentration of Vemurafenib can be decreased when it is combined with Folic Acid.Approved, Nutraceutical, Vet Approved
FormoterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Vemurafenib.Approved
FosaprepitantThe serum concentration of Vemurafenib can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Vemurafenib.Approved
FosnetupitantThe serum concentration of Fosnetupitant can be decreased when it is combined with Vemurafenib.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Vemurafenib.Approved, Investigational
FostamatinibThe serum concentration of Fostamatinib can be decreased when it is combined with Vemurafenib.Approved, Investigational
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Vemurafenib.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Vemurafenib.Approved, Investigational
Fusidic AcidThe serum concentration of Vemurafenib can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Vemurafenib.Approved
GarenoxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Vemurafenib.Approved, Investigational
GeldanamycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Geldanamycin.Experimental, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Vemurafenib.Approved
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Vemurafenib.Approved
GemifloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Genistein can be increased when it is combined with Vemurafenib.Investigational
GepironeThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Gepirone.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Vemurafenib.Experimental
GivinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Givinostat.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Vemurafenib.Approved, Investigational
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Vemurafenib.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Vemurafenib.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Vemurafenib.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Vemurafenib.Approved
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanabenzThe serum concentration of Guanabenz can be increased when it is combined with Vemurafenib.Approved, Investigational
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Vemurafenib.Approved, Investigational
HalofantrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Haloperidol.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
HeroinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Heroin.Approved, Illicit, Investigational
HesperetinThe serum concentration of Hesperetin can be increased when it is combined with Vemurafenib.Approved
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Vemurafenib.Approved
HexoprenalineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hexoprenaline.Approved, Withdrawn
HistamineThe serum concentration of Histamine can be decreased when it is combined with Vemurafenib.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Vemurafenib.Approved
HydrocodoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Vemurafenib.Approved, Vet Approved
HydromorphoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hydromorphone.Approved, Illicit
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Vemurafenib.Approved, Investigational
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Vemurafenib.Approved
HypericinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hypericin.Investigational
IbandronateIbandronate may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Vemurafenib.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Vemurafenib.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ibutilide.Approved
IcotinibThe serum concentration of Icotinib can be increased when it is combined with Vemurafenib.Approved, Investigational
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Vemurafenib.Approved
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Vemurafenib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Vemurafenib.Approved
ImidafenacinThe serum concentration of Imidafenacin can be decreased when it is combined with Vemurafenib.Approved, Investigational
ImipramineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Imipramine.Approved
Imipramine oxideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Imipramine oxide.Experimental
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Vemurafenib.Approved, Investigational
IndacaterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Indacaterol.Approved
IndalpineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Vemurafenib.Approved
IndinavirThe serum concentration of Vemurafenib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Vemurafenib.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vemurafenib.Approved, Investigational
IpecacThe serum concentration of Ipecac can be decreased when it is combined with Vemurafenib.Approved, Withdrawn
IpilimumabThe risk or severity of increased transaminases can be increased when Vemurafenib is combined with Ipilimumab.Approved
IpratropiumThe serum concentration of Ipratropium bromide can be decreased when it is combined with Vemurafenib.Approved
IprindoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Iprindole.Experimental
IproclozideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Iproniazid.Withdrawn
IrbesartanThe serum concentration of Irbesartan can be increased when it is combined with Vemurafenib.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Vemurafenib.Approved, Investigational
IsavuconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isocarboxazid.Approved
IsoconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isoconazole.Approved
IsoetarineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isoetarine.Approved
IsofluraneThe serum concentration of Isoflurane can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
IsoprenalineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Vemurafenib.Approved, Investigational
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Vemurafenib.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Vemurafenib.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Itraconazole.Approved, Investigational
IvabradineVemurafenib may increase the QTc-prolonging activities of Ivabradine.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Vemurafenib.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Vemurafenib.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Vemurafenib.Approved, Investigational
JosamycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Josamycin.Approved, Investigational
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Vemurafenib.Approved
KetobemidoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Kitasamycin.Experimental
L-TryptophanThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Vemurafenib.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Vemurafenib.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Vemurafenib.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Vemurafenib.Experimental
LanicemineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lanicemine.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Vemurafenib.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Vemurafenib.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Vemurafenib.Investigational
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Vemurafenib.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Vemurafenib.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Vemurafenib.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Vemurafenib.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Vemurafenib.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Vemurafenib.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Vemurafenib.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Vemurafenib.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Vemurafenib.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Vemurafenib.Approved, Investigational
LevorphanolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Levorphanol.Approved
LevosalbutamolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Levosalbutamol.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Vemurafenib.Approved
LicofeloneThe serum concentration of Licofelone can be increased when it is combined with Vemurafenib.Investigational
LidocaineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Vemurafenib.Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Vemurafenib.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lithium.Experimental
LofentanilThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lofentanil.Illicit
LofepramineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lofepramine.Experimental
LofexidineThe serum concentration of Lofexidine can be increased when it is combined with Vemurafenib.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lomefloxacin.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Vemurafenib.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Vemurafenib.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Vemurafenib.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Vemurafenib.Approved, Investigational
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Vemurafenib.Approved
LorpiprazoleThe serum concentration of Vemurafenib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Vemurafenib.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Vemurafenib.Approved, Investigational
LoxapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Loxapine.Approved
LuliconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Luliconazole.Approved
LumacaftorThe metabolism of Vemurafenib can be increased when combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lumefantrine.Approved
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Vemurafenib.Approved, Investigational
LurasidoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lurasidone.Approved, Investigational
MacimorelinThe serum concentration of Macimorelin can be decreased when it is combined with Vemurafenib.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Vemurafenib.Approved
MalathionThe serum concentration of Malathion can be increased when it is combined with Vemurafenib.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Vemurafenib.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Maprotiline.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Vemurafenib.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
Medical CannabisThe serum concentration of Medical Cannabis can be decreased when it is combined with Vemurafenib.Experimental, Investigational
MedifoxamineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Medifoxamine.Experimental
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Vemurafenib.Approved, Investigational
Mefenamic acidThe serum concentration of Mefenamic acid can be increased when it is combined with Vemurafenib.Approved
MefloquineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mefloquine.Approved, Investigational
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Vemurafenib.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Melitracen.Experimental, Investigational
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
MelperoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Melperone.Approved, Investigational
MenadioneThe serum concentration of Menadione can be increased when it is combined with Vemurafenib.Approved, Nutraceutical
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Vemurafenib.Investigational, Withdrawn
MeptazinolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mesoridazine.Approved, Investigational
MethadoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Methadyl Acetate.Approved, Illicit
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Vemurafenib.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Vemurafenib.Approved
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Methotrimeprazine.Approved, Investigational
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Vemurafenib.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be decreased when it is combined with Vemurafenib.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Vemurafenib.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Vemurafenib.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Vemurafenib.Experimental
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Vemurafenib.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Vemurafenib.Approved
MexiletineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mexiletine.Approved, Investigational
MianserinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mianserin.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Vemurafenib.Investigational, Withdrawn
MiconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Vemurafenib.Approved, Illicit
MidecamycinThe serum concentration of Midecamycin can be decreased when it is combined with Vemurafenib.Approved
MidostaurinThe serum concentration of Midostaurin can be decreased when it is combined with Vemurafenib.Approved, Investigational
MifepristoneVemurafenib may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Minaprine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Vemurafenib.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Vemurafenib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Vemurafenib.Approved, Investigational
MizoribineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mizoribine.Investigational
MocetinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mocetinostat.Investigational
MoclobemideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Vemurafenib.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Vemurafenib.Approved
MolindoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Molindone.Approved
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Vemurafenib.Approved
MoperoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Moperone.Experimental
MorphineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mosapramine.Experimental
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Moxifloxacin.Approved, Investigational
MuraglitazarThe serum concentration of Muraglitazar can be increased when it is combined with Vemurafenib.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Vemurafenib.Approved, Investigational
NabiximolsThe serum concentration of Nabiximols can be decreased when it is combined with Vemurafenib.Approved, Investigational
NabumetoneThe serum concentration of Nabumetone can be increased when it is combined with Vemurafenib.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Vemurafenib.Approved
NalbuphineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nalbuphine.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Vemurafenib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Vemurafenib.Approved, Vet Approved
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Vemurafenib.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Vemurafenib.Approved, Investigational
NefazodoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Vemurafenib can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nemonoxacin.Investigational
NeratinibThe serum concentration of Neratinib can be decreased when it is combined with Vemurafenib.Approved, Investigational
NetupitantThe serum concentration of Vemurafenib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Vemurafenib.Approved
NialamideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nialamide.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Vemurafenib.Approved, Investigational
NicomorphineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nicomorphine.Experimental
NicotineThe serum concentration of Nicotine can be increased when it is combined with Vemurafenib.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Vemurafenib.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Vemurafenib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Vemurafenib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Vemurafenib.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Vemurafenib.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Vemurafenib.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Vemurafenib.Approved, Investigational
Nitric OxideThe serum concentration of Nitric Oxide can be increased when it is combined with Vemurafenib.Approved
NitrofurantoinThe serum concentration of Vemurafenib can be decreased when it is combined with Nitrofurantoin.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Vemurafenib.Approved
NomifensineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nomifensine.Withdrawn
NorepinephrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Norepinephrine.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Vemurafenib.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Norfloxacin.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Vemurafenib.Approved
NormethadoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nortriptyline.Approved
OBP-801The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with OBP-801.Investigational
OctreotideOctreotide may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Vemurafenib.Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Vemurafenib.Approved
OleandomycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oleandomycin.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Vemurafenib.Experimental, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Olodaterol.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Vemurafenib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Vemurafenib.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Omoconazole.Experimental
OndansetronThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ondansetron.Approved
OpipramolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Opipramol.Investigational
OpiumThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Orciprenaline.Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Vemurafenib.Approved
OrvepitantThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Orvepitant.Investigational
OsanetantThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Vemurafenib.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Vemurafenib.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Vemurafenib.Approved
OxaflozaneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxaflozane.Experimental
OxaliplatinThe serum concentration of Oxaliplatin can be increased when it is combined with Vemurafenib.Approved, Investigational
OxaprotilineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxaprotiline.Experimental
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Vemurafenib.Approved
OxiconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxiconazole.Approved
OxitriptanThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxitriptan.Approved, Investigational, Nutraceutical
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxolinic acid.Experimental
OxtriphyllineThe serum concentration of Oxtriphylline can be increased when it is combined with Vemurafenib.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Vemurafenib.Approved, Investigational
OxycodoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxypertine.Experimental
OxytocinOxytocin may increase the QTc-prolonging activities of Vemurafenib.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Vemurafenib.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Vemurafenib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Paliperidone.Approved
PalonosetronThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Palonosetron.Approved, Investigational
PanobinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Vemurafenib.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Vemurafenib.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Vemurafenib.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Vemurafenib.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Vemurafenib.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Vemurafenib.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Vemurafenib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pazufloxacin.Investigational
PD173955The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with PD173955.Experimental
PefloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pefloxacin.Approved
PenfluridolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Penfluridol.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Vemurafenib can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Vemurafenib.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Vemurafenib.Approved
PerazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Perazine.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Vemurafenib.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Vemurafenib.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Vemurafenib.Approved, Investigational
PerospironeThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Perospirone.Approved
PerphenazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Perphenazine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Vemurafenib.Experimental
PethidineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pethidine.Approved
PF-00610355The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with PF-00610355.Investigational
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Vemurafenib.Withdrawn
PhenazocineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Vemurafenib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Phenoperidine.Experimental
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Vemurafenib.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Vemurafenib.Approved, Investigational
PhenylpropanolamineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Vemurafenib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Vemurafenib.Approved, Investigational
PICEATANNOLThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with PICEATANNOL.Experimental
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Vemurafenib.Approved, Investigational
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Vemurafenib.Approved, Investigational
PimozideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pimozide.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Vemurafenib.Approved
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Vemurafenib.Approved, Investigational
PipamperoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pipamperone.Approved, Investigational
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pipemidic acid.Experimental
PiperaquineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Piperaquine.Approved, Investigational
PipotiazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pirbuterol.Approved
PiritramideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Piritramide.Approved, Investigational
PirlindoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pirlindole.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Piromidic acid.Experimental
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Vemurafenib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Vemurafenib.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Vemurafenib.Approved, Investigational
PivagabineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pivagabine.Investigational
PizotifenThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pizotifen.Approved
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Vemurafenib.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Vemurafenib.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Vemurafenib.Approved, Investigational
PosaconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Posaconazole.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pracinostat.Investigational
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Vemurafenib.Approved, Investigational, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Vemurafenib.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Vemurafenib.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Vemurafenib.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Vemurafenib.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Vemurafenib.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Vemurafenib.Approved, Vet Approved
PrimaquineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Primaquine.Approved
PrimidoneThe metabolism of Vemurafenib can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Procainamide.Approved
ProcaterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Prochlorperazine.Approved, Vet Approved
ProgabideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Progabide.Approved, Investigational
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Vemurafenib.Approved, Vet Approved
ProguanilThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Proguanil.Approved
PromazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be decreased when it is combined with Vemurafenib.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Propafenone.Approved
PropericiazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Propericiazine.Approved, Investigational
PropiverineThe serum concentration of Propiverine can be decreased when it is combined with Vemurafenib.Approved, Investigational
PropofolThe serum concentration of Propofol can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Vemurafenib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Vemurafenib.Experimental
ProthipendylThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Prothipendyl.Investigational
ProtokylolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Prulifloxacin.Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Vemurafenib.Approved, Investigational
PyrimethamineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pyronaridine.Investigational
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Vemurafenib.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quetiapine.Approved
QuinacrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quinacrine.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quinine.Approved
QuinupramineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quinupramine.Experimental
R-306465The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with R-306465.Investigational
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Vemurafenib.Approved, Investigational
RacepinephrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Racepinephrine.Approved
RacloprideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Raclopride.Investigational
RadicicolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Radicicol.Experimental
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Vemurafenib.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Vemurafenib.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Vemurafenib.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Vemurafenib.Approved, Investigational
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Vemurafenib.Approved
RavuconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ravuconazole.Investigational
ReboxetineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Vemurafenib.Approved
RemifentanilThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Vemurafenib.Approved, Investigational
ReserpineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Reserpine.Approved, Investigational
ResveratrolThe serum concentration of Resveratrol can be increased when it is combined with Vemurafenib.Approved, Experimental, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Vemurafenib.Approved
RicolinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ricolinostat.Investigational
RifabutinThe serum concentration of Vemurafenib can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Vemurafenib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Vemurafenib can be decreased when it is combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Vemurafenib.Approved
RiluzoleThe serum concentration of Riluzole can be increased when it is combined with Vemurafenib.Approved, Investigational
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Vemurafenib.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Vemurafenib.Approved
RisperidoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ritanserin.Investigational
RitodrineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Vemurafenib.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Vemurafenib.Approved
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Vemurafenib.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Vemurafenib.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Vemurafenib.Approved, Investigational
RolipramThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Rolipram.Investigational
RomidepsinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Romidepsin.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Vemurafenib.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Vemurafenib.Approved
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Vemurafenib.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Vemurafenib.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Vemurafenib.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Vemurafenib.Approved, Investigational
RufloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Rufloxacin.Experimental
RupatadineThe serum concentration of Rupatadine can be decreased when it is combined with Vemurafenib.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Vemurafenib.Approved
SafinamideThe serum concentration of Safinamide can be decreased when it is combined with Vemurafenib.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Vemurafenib can be increased when it is combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Vemurafenib can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Vemurafenib.Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Vemurafenib.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Vemurafenib.Approved
SertaconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sertaconazole.Approved, Investigational
SertindoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sertraline.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
SibutramineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Vemurafenib.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Vemurafenib.Approved
SiltuximabThe serum concentration of Vemurafenib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Vemurafenib.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Vemurafenib.Approved
SinefunginThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sinefungin.Experimental
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Vemurafenib.Approved, Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Vemurafenib.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Vemurafenib.Approved
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Vemurafenib.Approved
SolithromycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Solithromycin.Investigational
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Vemurafenib.Approved, Investigational
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Vemurafenib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Vemurafenib.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sparfloxacin.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Vemurafenib.Experimental
SpiramycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Spiramycin.Approved
St. John's WortThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Vemurafenib.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Vemurafenib.Experimental
StiripentolThe serum concentration of Vemurafenib can be increased when it is combined with Stiripentol.Approved
SU4984The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with SU4984.Experimental
SufentanilThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sulconazole.Approved
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
SulfadoxineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sulfadoxine.Approved, Investigational
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Vemurafenib.Approved
SulfametopyrazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sulfametopyrazine.Approved, Withdrawn
SulfasalazineThe serum concentration of Vemurafenib can be decreased when it is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Vemurafenib.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Vemurafenib.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sultopride.Experimental
SumatriptanThe serum concentration of Vemurafenib can be decreased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Vemurafenib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Vemurafenib.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Vemurafenib.Approved
TacrineThe serum concentration of Tacrine can be increased when it is combined with Vemurafenib.Investigational, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Vemurafenib.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Vemurafenib.Approved, Investigational
TafenoquineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tafenoquine.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Vemurafenib.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Vemurafenib.Approved, Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tandutinib.Investigational
TapentadolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tapentadol.Approved
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Vemurafenib.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Vemurafenib.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Vemurafenib.Experimental
TazaroteneThe serum concentration of Tazarotene can be increased when it is combined with Vemurafenib.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Vemurafenib.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Vemurafenib.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Vemurafenib.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Temafloxacin.Withdrawn
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Vemurafenib.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Vemurafenib.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Vemurafenib.Approved
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Terbutaline.Approved
TerconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Terconazole.Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Vemurafenib.Approved, Withdrawn
TeriflunomideThe serum concentration of Vemurafenib can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Vemurafenib.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Vemurafenib.Approved, Investigational
Testosterone cypionateThe serum concentration of Testosterone cypionate can be decreased when it is combined with Vemurafenib.Approved
Testosterone enanthateThe serum concentration of Testosterone enanthate can be decreased when it is combined with Vemurafenib.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Testosterone undecanoate can be decreased when it is combined with Vemurafenib.Approved, Investigational
TetrabenazineThe risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Vemurafenib.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tetrahydropalmatine.Investigational
TezacaftorThe serum concentration of Tezacaftor can be decreased when it is combined with Vemurafenib.Approved, Investigational
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Vemurafenib.Approved, Investigational, Withdrawn
TheobromineThe serum concentration of Theobromine can be increased when it is combined with Vemurafenib.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Vemurafenib.Approved
ThiabendazoleThe serum concentration of Thiabendazole can be increased when it is combined with Vemurafenib.Approved, Vet Approved
ThiopropazateThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Vemurafenib.Approved, Withdrawn
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Vemurafenib.Approved, Investigational
ThiothixeneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Thiothixene.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Vemurafenib.Approved, Investigational
TianeptineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Vemurafenib.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Vemurafenib.Approved
TilidineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tilidine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Vemurafenib.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Vemurafenib.Approved, Investigational
TioconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tioconazole.Approved
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Vemurafenib.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Vemurafenib.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Vemurafenib.Approved, Investigational
TocilizumabThe serum concentration of Vemurafenib can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe serum concentration of Tocofersolan can be decreased when it is combined with Vemurafenib.Approved
TocopherolThe serum concentration of Tocopherol can be decreased when it is combined with Vemurafenib.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Vemurafenib.Approved, Investigational
TofisopamThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tofisopam.Approved
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Vemurafenib.Approved, Investigational
ToloxatoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Toloxatone.Approved
TolperisoneThe serum concentration of Tolperisone can be increased when it is combined with Vemurafenib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Vemurafenib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Vemurafenib.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Vemurafenib.Approved, Investigational
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Vemurafenib.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Vemurafenib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Vemurafenib.Approved, Investigational
TramadolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tramadol.Approved, Investigational
TranylcypromineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tranylcypromine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Vemurafenib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Vemurafenib.Approved, Investigational
TrazodoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Vemurafenib.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Vemurafenib.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Vemurafenib.Approved, Vet Approved
TriamtereneThe serum concentration of Triamterene can be increased when it is combined with Vemurafenib.Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Vemurafenib.Approved, Investigational
TrifluoperazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Vemurafenib.Approved
TrimethoprimThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trimipramine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Vemurafenib.Approved, Vet Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Vemurafenib.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Vemurafenib.Approved
TropisetronThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tropisetron.Approved, Investigational
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TylosinThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Vemurafenib.Approved, Investigational, Nutraceutical
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Vemurafenib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Vemurafenib.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Vemurafenib.Approved
VadimezanThe serum concentration of Vadimezan can be increased when it is combined with Vemurafenib.Investigational
ValbenazineThe serum concentration of Valbenazine can be decreased when it is combined with Vemurafenib.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Vemurafenib.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Valproic Acid.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Vemurafenib.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Vemurafenib.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Vemurafenib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Vemurafenib.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Vemurafenib.Approved, Investigational
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Vemurafenib.Approved, Investigational
VenlafaxineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Veralipride.Experimental
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Vemurafenib.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Vemurafenib.Investigational
VilanterolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Vilanterol.Approved
VilazodoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Vilazodone.Approved
ViloxazineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Viloxazine.Approved, Investigational, Withdrawn
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Vemurafenib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Vemurafenib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Vemurafenib.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Vemurafenib.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Vemurafenib.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Vemurafenib.Approved, Investigational
VoriconazoleThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Vorinostat.Approved, Investigational
VortioxetineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Vortioxetine.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Vemurafenib.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Vemurafenib.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Vemurafenib.Approved, Investigational, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Vemurafenib.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Vemurafenib.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Vemurafenib.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Vemurafenib.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Vemurafenib.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ziprasidone.Approved
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Vemurafenib.Approved, Investigational
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Vemurafenib.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Vemurafenib.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Vemurafenib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Vemurafenib.Approved
ZotepineThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. [PubMed:23094782]
  2. Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R: FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5. [PubMed:25096067]
  3. Luke JJ, Hodi FS: Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012 Jan 1;18(1):9-14. doi: 10.1158/1078-0432.CCR-11-2197. Epub 2011 Nov 14. [PubMed:22083257]
  4. Schirosi L, Strippoli S, Gaudio F, Graziano G, Popescu O, Guida M, Simone G, Mangia A: Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients? BMC Cancer. 2016 Nov 18;16(1):905. [PubMed:27863476]
  5. Stempel JM, Bustamante Alvarez JG, Carpio AM, Mittal V, Dourado C: Erdheim-Chester disease, moving away from the orphan diseases: A case report. Respir Med Case Rep. 2016 Dec 3;20:55-58. eCollection 2017. [PubMed:27995058]
  6. Zhang W, Heinzmann D, Grippo JF: Clinical Pharmacokinetics of Vemurafenib. Clin Pharmacokinet. 2017 Mar 2. doi: 10.1007/s40262-017-0523-7. [PubMed:28255850]
  7. Goldinger SM, Rinderknecht J, Dummer R, Kuhn FP, Yang KH, Lee L, Ayala RC, Racha J, Geng W, Moore D, Liu M, Joe AK, Bazan SP, Grippo JF: A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacol Res Perspect. 2015 Mar;3(2):e00113. doi: 10.1002/prp2.113. [PubMed:25729580]
  8. Roche news [Link]
  9. FDA News and Events [Link]
  10. FDA Vemurafenib application [Link]
External Links
KEGG Drug
D09996
PubChem Compound
42611257
PubChem Substance
175427131
ChemSpider
24747352
BindingDB
50396483
ChEBI
63637
ChEMBL
CHEMBL1229517
PharmGKB
PA165946873
HET
032
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vemurafenib
ATC Codes
L01XE15 — Vemurafenib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
3og7 / 4rzv / 5hes
FDA label
Download (304 KB)
MSDS
Download (51 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentClinical Stage III Cutaneous Melanoma AJCC v8 / Pathologic Stage III Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IIID Cutaneous Melanoma AJCC v81
0RecruitingTreatmentMalignant Melanoma of Skin / Melanoma (Skin) / Skin Cancers / Skin Carcinoma1
0RecruitingTreatmentPediatric Recurrent/Refractory BRAFV600E-mutant Gliomas1
1Active Not RecruitingTreatmentAdvanced Cancers2
1Active Not RecruitingTreatmentCancer, Advanced / Tumors, Solid1
1Active Not RecruitingTreatmentCarcinoma, Colorectal / Malignant Melanoma1
1Active Not RecruitingTreatmentMalignant Melanoma1
1Active Not RecruitingTreatmentMelanoma3
1CompletedNot AvailableMalignant Melanoma, Neoplasms2
1CompletedBasic ScienceMalignant Melanoma, Cancer1
1CompletedOtherMalignant Melanoma, Neoplasms1
1CompletedTreatmentMalignant Melanoma6
1CompletedTreatmentMalignant Melanoma, Neoplasms2
1CompletedTreatmentMetastatic Colorectal Cancers1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentThyroid Cancers1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentMelanoma1
1RecruitingTreatmentMelanoma / Skin Cancers1
1RecruitingTreatmentMetastatic Melanoma, BRAF V600 Mutation Positive1
1SuspendedTreatmentAdvanced or Inoperable Malignant Melanoma With BRAF Mutation1
1TerminatedTreatmentMalignant Melanoma1
1TerminatedTreatmentMelanoma2
1TerminatedTreatmentMelanoma / Metastatic Cancers1
1TerminatedTreatmentRecurrent Melanoma / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIc Melanoma / Stage IV Melanoma / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor / V600-mutated BRAF Metastatic Melanoma / V600-mutated BRAF Unresectable Melanoma1
1WithdrawnTreatmentBRAFV600 Mutation / Stage IV Melanoma1
1WithdrawnTreatmentMalignant Melanoma, Neoplasms1
1WithdrawnTreatmentMelanoma1
1WithdrawnTreatmentNeoplasms1
1WithdrawnTreatmentRecurrent Melanoma / Stage IV Melanoma / Tumors Metastatic to Brain1
1, 2Active Not RecruitingTreatmentBRAF-mutated Metastatic Melanoma / Melanoma / Metastatic Melanoma / V600EBRAF-mutated Metastatic Melanoma1
1, 2Active Not RecruitingTreatmentMelanoma1
1, 2Active Not RecruitingTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentBRAF Mutant Metastatic Melanoma1
1, 2RecruitingTreatmentMalignant Lymphomas / Tumors, Solid1
1, 2RecruitingTreatmentMelanoma3
1, 2TerminatedTreatmentAdvanced BRAF-mutant Cancers1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingScreeningMetastatic Melanoma / Metastatic Melanoma, BRAF V600 Mutation Positive1
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentHairy Cell Leukemia (HCL)1
2Active Not RecruitingTreatmentMelanoma2
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentMetastatic Melanoma1
2CompletedTreatmentMalignant Melanoma3
2CompletedTreatmentMalignant Melanoma Stage IV1
2CompletedTreatmentMelanoma1
2CompletedTreatmentMelanoma [C04.557.465.625.650.510]1
2CompletedTreatmentMultiple Myeloma, Neoplasms1
2CompletedTreatmentNeoplasms1
2Not Yet RecruitingTreatmentMelanoma, Malignant, of Soft Parts1
2Not Yet RecruitingTreatmentMelanoma / Melanoma (Skin) / Melanoma Stage1
2RecruitingScreeningAdvanced Malignant Solid Neoplasm / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / Childhood Langerhans Cell Histiocytosis / Histiocytic Sarcoma (HS) / Juvenile Xanthogranuloma / Langerhans Cell Histiocytosis (LCH) / Malignant Gliomas / Malignant Lymphomas / Recurrent Central Nervous System Neoplasm / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma / Recurrent Gliomas / Recurrent Hepatoblastoma / Recurrent Langerhans Cell Histiocytosis / Recurrent Malignant Solid Neoplasm / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Peripheral Primitive Neuroectodermal Tumor / Refractory Central Nervous System Neoplasm / Refractory Childhood Malignant Germ Cell Tumor / Refractory Langerhans cell histiocytosis / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Rhabdoid Tumors / Stage III Childhood Non-Hodgkin Lymphoma / Stage III Osteosarcoma / Stage III Osteosarcoma AJCC v7 / Stage III Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma AJCC v7 / Stage IV Childhood Non-Hodgkin Lymphoma / Stage IV Osteosarcoma / Stage IV Osteosarcoma AJCC v7 / Stage IV Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma AJCC v7 / Stage IVA Osteosarcoma / Stage IVA Osteosarcoma AJCC v7 / Stage IVB Osteosarcoma / Stage IVB Osteosarcoma AJCC v7 / Wilms' tumor1
2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / BRAF NP_004324.2:p.V600X / Ependymomas / Ewing's Sarcoma (ES) / Hepatoblastomas / Histiocytosis / Langerhans Cell Histiocytosis (LCH) / Malignant Germ Cell Tumor / Malignant Gliomas / Peripheral Primitive Neuroectodermal Tumor / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Neuroblastoma / Refractory Central Nervous System Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Refractory Non-Hodgkin's lymphoma / Rhabdoid Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic / Soft Tissue Sarcoma (STS) / Stage III Childhood Non-Hodgkin Lymphoma / Stage IV Childhood Non-Hodgkin Lymphoma / Wilms' tumor1
2RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAnaplastic Thyroid Carcinoma / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Poorly Differentiated Thyroid Cancer1
2RecruitingTreatmentBRAF V600 mutation / Malignant Melanoma Stage IV / Metastatic Brain Tumors1
2RecruitingTreatmentBRAF V600E Mutation Present / Papillary Craniopharyngioma1
2RecruitingTreatmentCancer of Unknown Primary Site1
2RecruitingTreatmentCancers / Neoplasia / Neoplasms / Tumors1
2RecruitingTreatmentHairy Cell Leukemia (HCL) / Leukemias1
2RecruitingTreatmentHematologic Cancers / Metastatic Cancers / Tumors, Solid1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentMalignant Melanoma2
2RecruitingTreatmentMelanoma1
2RecruitingTreatmentNeoplasms1
2RecruitingTreatmentRare Tumor / Refractory Tumors1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentThyroid Cancers1
2SuspendedTreatmentColorectal Cancers1
2TerminatedTreatmentActive Melanoma Brain Metastases1
2TerminatedTreatmentMalignant Melanoma2
2TerminatedTreatmentMelanoma3
2TerminatedTreatmentMelanoma / Metastatic Melanoma1
2TerminatedTreatmentMetastatic Melanoma (Carrying BRAF V600 Mutation)1
2Unknown StatusTreatmentMalignant Melanoma1
2WithdrawnTreatmentStage IIIB-C Melanoma1
3Active Not RecruitingTreatmentMalignant Melanoma1
3Active Not RecruitingTreatmentMalignant Melanoma / Melanoma1
3Active Not RecruitingTreatmentMelanoma2
3CompletedTreatmentMalignant Melanoma2
3RecruitingTreatmentMelanoma1
3WithdrawnTreatmentMelanoma1
4Active Not RecruitingTreatmentMalignant Melanoma1
4RecruitingTreatmentNeoplasms1
Not AvailableActive Not RecruitingNot AvailableMelanoma1
Not AvailableActive Not RecruitingDiagnosticAdvanced Solid Tumors / Cancers1
Not AvailableActive Not RecruitingTreatmentThyroid Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral240 mg
Tablet, film coatedOral240 mg
Tablet, film coatedOral240 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8470818No2006-08-022026-08-02Us
US8143271No2006-06-212026-06-21Us
US7863288No2009-06-202029-06-20Us
US7504509No2006-10-222026-10-22Us
US8741920No2010-07-272030-07-27Us
US9447089No2012-06-062032-06-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)272°CMSDS
water solubility<1 mg/mL MSDS
logP5.1MSDS
Caco2 permeability2.9E-06FDA review
pKa7.1Royal Soc Chem
Predicted Properties
PropertyValueSource
Water Solubility0.000362 mg/mLALOGPS
logP4.95ALOGPS
logP4.62ChemAxon
logS-6.1ALOGPS
pKa (Strongest Acidic)7.17ChemAxon
pKa (Strongest Basic)3.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.92 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity121.97 m3·mol-1ChemAxon
Polarizability48.1 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.745
Caco-2 permeable-0.6222
P-glycoprotein substrateNon-substrate0.6215
P-glycoprotein inhibitor INon-inhibitor0.5884
P-glycoprotein inhibitor IINon-inhibitor0.699
Renal organic cation transporterNon-inhibitor0.864
CYP450 2C9 substrateNon-substrate0.7628
CYP450 2D6 substrateNon-substrate0.8038
CYP450 3A4 substrateSubstrate0.5645
CYP450 1A2 substrateInhibitor0.5762
CYP450 2C9 inhibitorInhibitor0.5987
CYP450 2D6 inhibitorNon-inhibitor0.7329
CYP450 2C19 inhibitorInhibitor0.6508
CYP450 3A4 inhibitorInhibitor0.7061
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9553
Ames testNon AMES toxic0.6323
CarcinogenicityNon-carcinogens0.7229
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5179 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6688
hERG inhibition (predictor II)Non-inhibitor0.5302
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0024900000-4911e6c7ad52fd2c2896

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Phenylpyridines / Sulfanilides / Pyrrolopyridines / Benzoyl derivatives / Chlorobenzenes / Fluorobenzenes / Organosulfonamides / Organic sulfonamides / Aryl chlorides / Aryl fluorides
show 12 more
Substituents
Aryl-phenylketone / 3-phenylpyridine / Sulfanilide / Pyrrolopyridine / Benzoyl / Halobenzene / Fluorobenzene / Chlorobenzene / Aryl chloride / Aryl halide
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, sulfonamide, organochlorine compound, pyrrolopyridine (CHEBI:63637)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, a...
Gene Name
BRAF
Uniprot ID
P15056
Uniprot Name
Serine/threonine-protein kinase B-raf
Molecular Weight
84436.135 Da
References
  1. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. [PubMed:23094782]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. [PubMed:23094782]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. [PubMed:23094782]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. [PubMed:23094782]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF: Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012 Jul;342(1):33-40. doi: 10.1124/jpet.112.192195. Epub 2012 Mar 27. [PubMed:22454535]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF: Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012 Jul;342(1):33-40. doi: 10.1124/jpet.112.192195. Epub 2012 Mar 27. [PubMed:22454535]

Drug created on May 20, 2013 00:41 / Updated on July 19, 2018 17:49